Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Grifols acquires intellectual property for post-polio treatment

Grifols acquires intellectual property for post-polio treatment

21st May 2010

Grifols has confirmed the acquisition of intellectual property rights associated with the treatment of post-polio syndrome (PPS).

The announcement follows an agreement between Grifols and Swedish company Pharmalink AB, which will transfer documentation, know-how and Swedish regulatory approvals to the firm.

In addition, Grifols is set to acquire US, European and Japanese patents for a specific PPS treatment method that uses human immunoglobulin.

Ramon Riera, director of global sales and marketing at the company, said the new developments are “consistent with our mission of developing therapies for chronically ill and underserved patient populations”.

Meanwhile, Grifols’ interest in exploring PPS treatments was welcomed by Joan Headley, executive director of Post-Polio Health International.

“It has been challenging to find treatments for this condition. We are pleased that Grifols is investing in the PPS community,” she commented.

The prevalence of PPS, which is characterised by muscle weakness, fatigue and pain among polio sufferers, has been estimated at between 25 and 50 per cent by the US National Institute of Neurological Disorders and Stroke.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.